Korean J Urol.  2015 Jul;56(7):498-504. 10.4111/kju.2015.56.7.498.

Prognostic impact of preoperative statin use after radical nephroureterectomy for upper urinary tract urothelial carcinoma

• Lim JH
• Jeong IG
• Park JY
• You D
• Hong B
• Hong JH
• Ahn H
• Kim CS

• KMID: 2160646
• DOI: http://doi.org/10.4111/kju.2015.56.7.498

Abstract

PURPOSE
The objective was to investigate the impact of statin use on prognosis after radical nephroureterectomy for upper urinary tract urothelial carcinoma (UTUC).
MATERIALS AND METHODS
A retrospective review of medical records identified 277 patients who underwent radical nephroureterectomy for primary UTUC at Asan Medical Center between January 2006 and December 2011. Information on preoperative statin use was obtained from patient charts in an electronic database. We assessed the impact of statin use on recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS).
RESULTS
Of these 277 patients, 62 (22.4%) were taking statin medications. Compared to the statin nonusers, the statin users were older, had a higher body mass index, and had higher rates of cardiovascular disease and diabetes. The 5-year RFS rates of statin users and nonusers were 78.5% and 72.5%, respectively (p=0.528); the 5-year CSS rates were 85.6% and 77.7%, respectively (p=0.516); and the 5-year OS rates were 74.5% and 71.4%, respectively (p=0.945). In the multivariate analysis, statin use was not an independent prognostic factor for RFS (hazard ratio, 0.47; p=0.056), CSS (hazard ratio, 0.46; p=0.093), or OS (hazard ratio, 0.59; p=0.144) in patients who underwent radical nephroureterectomy for UTUC.
CONCLUSIONS
Statin use was not associated with improved RFS, CSS, or OS in the sample population of patients with UTUC.

Keyword

Carcinoma; Hydroxymethylglutaryl-CoA reductase inhibitors; Transitional cell carcinoma

MeSH Terms

Aged
Carcinoma, Transitional Cell/pathology/*surgery
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
Kidney Neoplasms/pathology/*surgery
Male
Middle Aged
Neoplasm Grading
Neoplasm Staging
Nephrectomy/methods
Preoperative Care/methods
Prognosis
Recurrence
Retrospective Studies
Survival Analysis
Ureteral Neoplasms/pathology/*surgery
Hydroxymethylglutaryl-CoA Reductase Inhibitors

Figure

• 

  Fig. 1 (A) Recurrence-free survival in statin users and nonusers. (B) Cancer-specific survival in statin users and nonusers. (C) Overall survival in statin users and nonusers.

Reference

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64:9–29.

2. Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998; 52:594–601.

3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366:1267–1278.

4. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer. 2007; 120:833–843.

5. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012; 367:1792–1802.

6. Dulak J, Jozkowicz A. Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Curr Cancer Drug Targets. 2005; 5:579–594.

7. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005; 4:977–987.

8. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002; 16:508–519.

9. Kamat AM, Nelkin GM. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology. 2005; 66:1209–1212.

10. da Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, et al. Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol. 2013; 190:487–492.

11. Crivelli JJ, Xylinas E, Kluth LA, da Silva RD, Chrystal J, Novara G, et al. Effect of statin use on outcomes of non-muscleinvasive bladder cancer. BJU Int. 2013; 112:E4–E12.

12. Tsai HK, Katz MS, Coen JJ, Zietman AL, Kaufman DS, Shipley WU. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer. Urology. 2006; 68:1188–1192.

13. Xylinas E, Kluth LA, Crivelli JJ, Rieken M, Margulis V, Seitz C, et al. Impact of statin use on oncologic outcomes of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. Eur Urol. 2013; 63:1134–1135.

14. Owens WD, Felts JA, Spitznagel EL Jr. ASA physical status classifications: a study of consistency of ratings. Anesthesiology. 1978; 49:239–243.

15. May M, Brookman-Amissah S, Roigas J, Hartmann A, Storkel S, Kristiansen G, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a multicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol. 2010; 57:850–858.

16. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17:1471–1474.

17. Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, et al. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol. 2010; 57:1064–1071.

18. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, et al. Statin use and risk of prostate cancer in the California Men's Health Study cohort. Cancer Epidemiol Biomarkers Prev. 2007; 16:2218–2225.

19. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst. 2006; 98:1819–1825.

20. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer. 2008; 123:899–904.

21. Mondul AM, Han M, Humphreys EB, Meinhold CL, Walsh PC, Platz EA. Association of statin use with pathological tumor characteristics and prostate cancer recurrence after surgery. J Urol. 2011; 185:1268–1273.

22. Song C, Park S, Park J, Shim M, Kim A, Jeong IG, et al. Statin use after radical prostatectomy reduces biochemical recurrence in men with prostate cancer. Prostate. 2015; 75:211–217.

23. Sebti SM, Tkalcevic GT, Jani JP. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Cancer Commun. 1991; 3:141–147.

24. Zhang XL, Geng J, Zhang XP, Peng B, Che JP, Yan Y, et al. Statin use and risk of bladder cancer: a meta-analysis. Cancer Causes Control. 2013; 24:769–776.

25. Hoffmann P, Roumeguère T, Schulman C, van Velthoven R. Use of statins and outcome of BCG treatment for bladder cancer. N Engl J Med. 2006; 355:2705–2707.

26. Kamat AM, Wu X. Statins and the effect of BCG on bladder cancer. N Engl J Med. 2007; 356:1276.

27. Skolarus TA, Lee EW, Virgo KS, Katz MD, Hudson MA, Kibel AS, et al. Intravesical bacille Calmette-Guérin therapy for non+muscle-invasive bladder cancer: effects of concurrent statin therapy. J Am Coll Surg. 2009; 209:248–253.

28. Berglund RK, Savage CJ, Vora KC, Kurta JM, Cronin AM. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder. J Urol. 2008; 180:1297–1300.

29. Geleedst-De Vooght M, Maitland-van der Zee AH, Schalekamp T, Mantel-Teeuwisse A, Jansen P. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study. Drugs Aging. 2010; 27:589–596.